首页> Cancer management and research> Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.

导出 LinkOut

翻译打印收藏纠错

第一作者： Francesco,Facchinetti

第一单位： Predictive Biomarkers and Novel Therapeutic Strategies in Oncology, Inserm U981, Gustave Roussy Cancer Center, Villejuif, France.;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.

作者： Francesco,Facchinetti ^[1] ; Antonin,Levy ^[2] ; Samy,Ammari ^[3] ; Charles,Naltet ^[4] ; Pernelle,Lavaud ^[4] ; Mihaela,Aldea ^[4] ; Damien,Vasseur ^[5] ; David,Planchard ^[4] ; Benjamin,Besse ^[6]

作者单位： Predictive Biomarkers and Novel Therapeutic Strategies in Oncology, Inserm U981, Gustave Roussy Cancer Center, Villejuif, France.;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France. ^[1] Department of Radiation Oncology, Institut d'Oncologie Thoracique (IOT), Gustave Roussy Cancer Center, Villejuif, France.;INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France. ^[2] Department of Radiology, Gustave Roussy Cancer Center, Villejuif, France. ^[3] Department of Medical Oncology, Institut d'Oncologie Thoracique (IOT), Gustave Roussy Cancer Center, Villejuif, France. ^[4] Department of Medical Biology and Pathology, Gustave Roussy Cancer Center, Villejuif, France. ^[5] Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.;Department of Medical Oncology, Institut d'Oncologie Thoracique (IOT), Gustave Roussy Cancer Center, Villejuif, France. ^[6]

关键词 CNS TKI brain central nervous system lung cancer radiotherapy tyrosine kinase inhibitors

DOI 10.2147/CMAR.S292730

PMID 33814929

发布时间 2022-04-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交